Peptipedia
Growth HormoneIn Clinical TrialsClinical Trials

CJC-1295

Also known as CJC-1295 no DAC, Modified GRF 1-29

A synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates GH release from the pituitary.

Investigational - Phase II trial discontinued (precautionary termination)
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

100 mcg daily (no DAC)

Frequency

Daily (no DAC)

Duration

8-12 weeks

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 100 mcg daily (no DAC) via Subcutaneous injection, Daily (no DAC). Dose range: 100-300 mcg per dose (no DAC). Duration: 8-12 weeks.

Timing & Administration

Administer via Subcutaneous injection. Frequency: Daily (no DAC).

Mechanism of Action

Binds to GHRH receptors on the pituitary, stimulating GH synthesis and release.

Research Summary

Evidence level: clinical trials. Clinical status: Investigational - Phase II trial discontinued (precautionary termination).

Side Effects & Safety

Important Warnings

  • Immunogenicity risk
  • Caution with active cancer.
Injection site reactions
facial flushing
headache
water retention
dizziness
potential histamine release
cancer concerns

References

No references available.

Related Peptides

Browse all →
IpamorelinGrowth Hormone

A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin.

View profile
TesamorelinGrowth Hormone

An FDA-approved GHRH analog used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy.

View profile
GHRP-6Growth Hormone

One of the first synthetic GH secretagogues developed. Strongly stimulates GH release and significantly increases appetite.

View profile